Publication date: Mar 01, 2025
Myalgic encephalomyelitis (ME) is associated with long COVID and also untoward sequelae after anti-coronavirus vaccination. Recently, oral minocycline therapy has been reported to ameliorate symptoms in patients with ME, particularly at the initial stage of the disease. Oral minocycline (100 mg cD7 2 on the first day, followed by 100 mg/day for 41 days) was administered to 55 patients with ME that emerged during the “Corona era,” including 19 patients with long COVID and 5 patients diagnosed with untoward sequalae following coronavirus vaccination. Acute adverse effects including nausea and/or dizziness caused four (7 %) patients to discontinue treatment in the first few days. Among the other 51 patients who completed therapy, favorable effects were observed, including a decrease in performance status score or index for restricted activities of daily living ≥2 points in 41 (80 %) patients. Disease duration was inversely associated with the favorable therapeutic effects (p = 0. 02) and the disease duration within 6 months was significantly associated with the favorable therapeutic effects (27/30, 90 %, p = 0. 02, hazard ratio: 3. 6, 95 % confidence interval, 1. 2-10. 6). The favorable effects were observed in 16 (89 %) of 18 patients with long COVID. Significant amelioration of subjective symptoms of fatigue, post-exertional malaise, unrefreshing sleep, brain fog, disequilibrium, orthostatic intolerance, and neuropathic pain were observed. Oral minocycline was effective at ameliorating symptoms in patients with ME including long COVID and post-coronavirus vaccination sequalae. It represents an effective first-line therapeutic option for these patients in the initial stage.
Open Access PDF
Concepts | Keywords |
---|---|
100mg2 | Chronic fatigue syndrome |
Daily | Disequilibrium |
Malaise | Long COVID |
Pilot | Minocycline |
Vaccination | Myalgic encephalomyelitis |
Post-coronavirus vaccination sequalae |
Semantics
Type | Source | Name |
---|---|---|
drug | DRUGBANK | Minocycline |
disease | MESH | Myalgic encephalomyelitis |
disease | MESH | long COVID |
disease | MESH | sequelae |
disease | MESH | brain fog |
disease | MESH | orthostatic intolerance |
disease | MESH | neuropathic pain |